脊髄小脳失調症(SCA)治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Spinocerebellar Ataxia (SCA) - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0618
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:96
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Spinocerebellar Ataxia (SCA) – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Spinocerebellar Ataxia (SCA) – Pipeline Review, H2 2019, provides an overview of the Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline landscape.

Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Symptoms include poor coordination, unsteady walk and a tendency to stumble, change in speech and difficulty swallowing.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Spinocerebellar Ataxia (SCA) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 2, 9, 3 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (SCA) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Spinocerebellar Ataxia (SCA) – Overview
Spinocerebellar Ataxia (SCA) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spinocerebellar Ataxia (SCA) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spinocerebellar Ataxia (SCA) – Companies Involved in Therapeutics Development
Allianz Pharmascience Ltd
Biohaven Pharmaceutical Holding Company Ltd
BioXcel Corp
Cadent Therapeutics Inc
Dystrogen Therapeutics SA
Everfront Biotech Inc
Exicure Inc
IntraBio Ltd
Ionis Pharmaceuticals Inc
Lacerta Therapeutics Inc
Sclnow Biotechnology Co Ltd
Seelos Therapeutics, Inc.
Shionogi & Co Ltd
Spark Therapeutics Inc
Steminent Biotherapeutics Inc
UniQure NV
Vybion Inc
Wave Life Sciences Ltd
Spinocerebellar Ataxia (SCA) – Drug Profiles
Spinocerebellar Ataxia (SCA) – Dormant Projects
Spinocerebellar Ataxia (SCA) – Discontinued Products
Spinocerebellar Ataxia (SCA) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Spinocerebellar Ataxia (SCA), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Allianz Pharmascience Ltd, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by BioXcel Corp, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Cadent Therapeutics Inc, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Dystrogen Therapeutics SA, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Everfront Biotech Inc, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Exicure Inc, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by IntraBio Ltd, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Lacerta Therapeutics Inc, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Sclnow Biotechnology Co Ltd, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Seelos Therapeutics, Inc., H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Shionogi & Co Ltd, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Spark Therapeutics Inc, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Steminent Biotherapeutics Inc, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by UniQure NV, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Vybion Inc, H2 2019
Spinocerebellar Ataxia (SCA) - Pipeline by Wave Life Sciences Ltd, H2 2019
Spinocerebellar Ataxia (SCA) - Dormant Projects, H2 2019

【掲載企業】

Allianz Pharmascience Ltd
Biohaven Pharmaceutical Holding Company Ltd
BioXcel Corp
Cadent Therapeutics Inc
Dystrogen Therapeutics SA
Everfront Biotech Inc
Exicure Inc
IntraBio Ltd
Ionis Pharmaceuticals Inc
Lacerta Therapeutics Inc
Sclnow Biotechnology Co Ltd
Seelos Therapeutics, Inc.
Shionogi & Co Ltd
Spark Therapeutics Inc
Steminent Biotherapeutics Inc
UniQure NV
Vybion Inc
Wave Life Sciences Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[脊髄小脳失調症(SCA)治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆